Daniel Sterman, MD
Pulmonary Disease · Philadelphia, PANPI 1851325922
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,032 of the $27,005 with a category attached, or 81.6%. 10 manufacturers reported payments, led by Gyrus ACMI, Inc. at 43.2% of the total. Reporting peaked in 2020 at $13,720 and has fallen 89.6% since, to $1,422 in 2025. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $551.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gyrus ACMI, Inc.$12K
- Spiration, Inc.$6K
- Intuitive Surgical$4K
- AstraZeneca$2K
- Galvanize Therapeutics, Inc$2K
- Boehringer Ingelheim International GmbH$970
- plus $337 from 4 others
Across 23 payments — averaging $16,136 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$318K
- Janssen Research & Development, LLC$53K
What the payments were for
- Consulting fees$22,03282%
- Travel & lodging$7053%
- Food & beverage$1,7366%
- Education$2,5329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gyrus ACMI, Inc. | 10 | $11,660 |
| Spiration, Inc. | 10 | $6,498 |
| Intuitive Surgical | 13 | $3,941 |
| AstraZeneca | 2 | $2,084 |
| Galvanize Therapeutics, Inc | 6 | $1,515 |
| Boehringer Ingelheim International GmbH | 4 | $970 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| Boehringer Ingelheim | 1 | $145 |
| Novocure Inc. | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,709
- TAGRISSO$2,084
- ALIYA SYSTEM$1,340
- XYWAV$150
- OFEV$145
How this compares
$27,005 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $41,899 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $12,911 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $12,481 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $6,454 |
| Arnuity ElliptaFluticasone Furoate | 20 | $4,747 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $837 |
| Ventolin HfaAlbuterol Sulfate | 15 | $775 |
| Montelukast Sodium | 14 | $97 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.